Nonalcoholic fatty liver disease (NAFLD) has reached epidemic proportions worldwide.
NAFLD and type 2 diabetes mellitus (T2DM) are known to frequently coexist and act …

Background Nonalcoholic fatty liver disease (NAFLD) comprises hepatic alterations with
increased lipid accumulation (steatosis) without or with inflammation (nonalcoholic …

To assess the efficacy of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) for
treatment of nonalcoholic fatty liver disease (NAFLD) or steatohepatitis (NASH), we …

Background Visceral and ectopic fat are key drivers of adverse cardiometabolic outcomes in
obesity. We aimed to evaluate the effects of injectable liraglutide 3· 0 mg daily on body fat …

Background and Aims Recent studies link NAFLD to an increased incidence of HCC and
extrahepatic cancers. However, earlier studies were small or lacked liver histology, which …

Evidence suggests a close connection between Nonalcoholic Fatty Liver Disease (NAFLD)
and increased cardiovascular (CV) risk. Several cross-sectional studies report that NAFLD is …

Background and Aims Due to their inherent characteristics, the function of group‐2 innate
lymphoid cells (ILC2s) varies in a context‐dependent manner. ILC2s are involved in certain …

Obesity contributes to reduced life expectancy because of its link with type 2 diabetes and
cardiovascular disease. Yet, targeting this poorly diagnosed, ill-defined, and …

Diabetes mellitus (DM) is a chronic and complex metabolic disorder and also an important
cause of cardiovascular (CV) disease (CVD). Patients with type 2 DM (T2DM) and obesity …

Introduction Nonalcoholic fatty liver disease (NAFLD) is a common comorbidity of type 2
diabetes mellitus (T2DM), and no approved therapies are currently available. A meta …